Texas is currently home to 4855 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Lung EpiCheck Biomarkers Development Study
NCT06245876
Recruiting
This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
02/08/2024
Locations: Urology San Antonio, San Antonio, Texas
Conditions: Lung Cancer
Register for Updates
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
NCT06258551
Recruiting
The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization period and evaluate if some populations of specific bacteria increase or decrease the risk of acquiring an infection or becoming colonized by pathogenic bacteria. Participants will have the following samples collected during enrollment: stool samples (maximum 2x/week), blood draws (1x/week), oral swab (1x/week).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Antimicrobial Drug Resistance, Antibiotic Resistant Infection, Clostridium Difficile, Carbapenem-Resistant Enterobacteriaceae Infection, Extended Spectrum Beta-Lactamase Producing Bacteria Infection, Vancomycin Resistant Enterococci Infection, Carbapenem Resistant Bacterial Infection, Vancomycin-Resistant Enterococcal Infection
Register for Updates
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
NCT05358379
Recruiting
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for which no standard therapy exists.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor, Adult Lymphoma
Register for Updates
Ocrelizumab for Psychosis by Autoimmunity
NCT03971487
Recruiting
Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to attack the body, similar to "friendly fire." Auto-antibodies attack brain receptors and then the person who has this problem begins to have hallucinations and other manifestations of schizophrenia, like feeling that people can see what they are thinking and... Read More
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
02/06/2024
Locations: Houston Methodist Research Institute, Houston, Texas
Conditions: Schizo-Affective Type of Psychosis, Schizophrenia
Register for Updates
Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
NCT03863145
Recruiting
Subjects will undergo baseline evaluation and an assessment of extent of disease. Subjects in Part 1 (Dose Escalation) will receive escalating doses of CB-03-10 based on a modified Fibonacci schema using a standard oncology 3+3 study design to define an MTD and a RP2D. Plasma PK samples will be collected at predetermined timepoints for all subjects. Subjects in Part 2 (Dose Expansion) of the study will receive CB-03-10 at the RP2D determined in the Part 1 of the study. The indications included... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Tranquil Clinical Research, Texas City, Texas
Conditions: Advanced Refractory Solid Tumors, Subjects Considered Likely to Respond to CB-03-10
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
NCT06258213
Recruiting
A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and multiple (Part 2) oral doses.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/05/2024
Locations: Worldwide Clinical Trials, San Antonio, Texas
Conditions: Gout
Register for Updates
Improving Adult Protective Services Client Outcomes: A Stepped-Care Social and Mental Health Engagement Program
NCT06257095
Recruiting
The purpose of this study is to ascertain the feasibility and effectiveness of an 8-week social engagement program aimed at reducing depression and increasing social engagement among seniors who are transitioning out of Adult Protective Services (APS) for either elder abuse or self-neglect.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/05/2024
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Depression in Old Age
Register for Updates
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
NCT05654532
Recruiting
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC699 that can be given safely to participants * Evaluate the safety profile of AC699 * Evaluate the pharmacokinetics of AC699 * Evaluate the effectiveness of AC699
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Site 03, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis
NCT04373473
Recruiting
The purpose of the study is to evaluate the efficacy and safety of lyophilized PRIM-DJ2727 capsules given orally in subjects with ulcerative colitis at remission stage. This study will also include longitudinal analyses of recipient's gut microbiota taxonomy and metagenomics to determine potential associations with clinical outcomes in context of active FMT or placebo administration.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Adults With Ulcerative Colitis
Register for Updates
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
NCT05761223
Recruiting
This is the first-in-human, multicenter, open-label Phase I/II study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of FB849 alone and in combination with pembrolizumab in subjects with advanced solid tumors for whom no standard therapy is available.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Mary Crowley Cancer Research Center, Dallas, Texas
Conditions: Advanced Solid Tumor
Register for Updates
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
NCT04137900
Recruiting
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: University of Texas Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas
Conditions: Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Register for Updates
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
NCT05953090
Recruiting
Vulvovaginal skin conditions, namely vaginal atrophy, lichen sclerosus, lichen simplex chronicus and lichen planus affecting the female adult population will be treated with a novel gel dressing to test the short- and long-term safety and efficacy of the device.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: WR-Global Medical Research, LLC, Dallas, Texas
Conditions: Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva, Lichen Planus of Vulva, Lichen Simplex of Vulva (Disorder)
Register for Updates